Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a Prospective, Open Phase ii Clinical Study in Patients With alK-positive Non-small Cell Lung Cancer Treated With Ensatinib After Second-generation ALK-TKI Resistance

NCT05178511 is registered in ClinicalTrials.gov with Li Zhang, MD as lead sponsor.

NCT NCT05178511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05178511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a Prospective, Open Phase ii Clinical Study in Patients With alK-positive Non-small Cell Lung Cancer Treated With Ensatinib After Second-generation ALK-TKI Resistance
Lead sponsor
Li Zhang, MD
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
December 31, 2024
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy of ensatinib in this subset of patients, second generation alk-tki is resistant, the diagnosis was alk positive nsclc